ストックスクリーナーアプリを入手
0.4659
6.92%
0.0307
前日終値:
$0.4352
開ける：
$0.44
24時間の取引高:
269.62K
Relative Volume:
0.35
時価総額：
$26.92M
収益：
-
当期純損益:
$-151.16M
株価収益率:
-0.1569
EPS:
-2.97
ネットキャッシュフロー:
$-130.08M
1週間 パフォーマンス:
-7.62%
1か月 パフォーマンス:
-5.04%
6か月 パフォーマンス:
-65.28%
1年 パフォーマンス:
-97.02%
1日の値動き範囲:
$0.44
$0.475
1週間の範囲:
$0.41
$0.5096
52週間の値動き範囲:
$0.41
$16.29
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
名前
Alx Oncology Holdings Inc
セクター
電話
650-466-7125
住所
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.4603 | 26.92M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.44 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.15 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
543.48 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.51 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.31 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-06 | 開始されました | UBS | Buy |
| 2021-02-10 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 開始されました | Credit Suisse | Outperform |
| 2020-08-11 | 開始されました | Jefferies | Buy |
| 2020-08-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Alx Oncology Holdings Inc (ALXO) 最新ニュース
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus
ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan
HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus
ALX Oncology Reports Q1 2025 Financial Results - TipRanks
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus
ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq
Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus
ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Will ALXO Make A Comeback In July? - RTTNews
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Holdings Raised by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Raises Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Was Alx Oncology Holdings Inc (ALXO)’s session last reading good? - uspostnews.com
Investor’s Delight: Alx Oncology Holdings Inc (ALXO) Closes Weak at 0.62, Down -4.90 - DWinneX
Alx Oncology Holdings Inc [ALXO] stock was sold by Pinto Shelly at the price of US$633.0 - knoxdaily.com
UBS Adjusts Price Target for ALX Oncology (ALXO) After Trial Out - GuruFocus
UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating - marketscreener.com
Market Momentum Report: Alx Oncology Holdings Inc (ALXO)’s Negative Close at 0.54 - DWinneX
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Yahoo
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia
ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC - Investing.com
ALX Oncology faces Nasdaq delisting over price rule By Investing.com - Investing.com South Africa
ALX Oncology Announces Encouraging Final Results from Phase 1 Tr - GuruFocus
Sector Update: Health Care - marketscreener.com
Alx Oncology Holdings Inc: Rising -96.84% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
ALX Oncology (ALXO) Reports Promising Phase 1 Trial Results for Evorpacept in B-Cell Lymphoma | ALXO Stock News - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC By Investing.com - Investing.com South Africa
ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity - marketscreener.com
ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025 - Nasdaq
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire
ALX Oncology stock falls on trial setback (ALXO:NASDAQ) - Seeking Alpha
ALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary Endpoints - Nasdaq
ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints - marketscreener.com
ALX Oncology (ALXO) Shares Update After Phase 2 Trials Yield Mixed Results | ALXO Stock News - GuruFocus
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evalua - GuruFocus
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire
ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer TrialsWhat's Next? - Stock Titan
Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India
ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa
Alx Oncology Holdings Inc (ALXO) 財務データ
収益
当期純利益
現金流量
EPS
Alx Oncology Holdings Inc (ALXO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
4.19%
0.27%
大文字化:
|
ボリューム (24 時間):